Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Garin, Nicolas ^a,b   Felix, Garance ^a   Chuard, Christian ^c   Genné, Daniel ^d   Carballo, Sebastian ^a   Hugli, Olivier ^e   Lamy, Olivier ^e   Marti, Christophe ^a   Nendaz, Mathieu ^a   Rutschmann, Olivier ^a   Harbarth, Stephan ^a   Perrier, Arnaud ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital Riviera   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

^d Centre Hospitalier de Bienne   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREATHING RATE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOXEMIA; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; AGE; COMMUNITY-ACQUIRED INFECTIONS; LENGTH OF STAY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PNEUMONIA; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME FACTOR; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84975885976     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157350     Document Type: Article

References (37)

1. Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67: 71-79. doi: 10.1136/thx.2009.129502 PMID: 20729232
2. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T (2014) The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 33: 1065-1079. doi: 10.1007/s10096-014-2067-1 PMID: 24532008
3. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H (2012) Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 55: 1114-1121. PMID: 22744885
4. Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, et al. (2015) Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrob Agents Chemother 59: 1119-1126. doi: 10.1128/AAC.03643-14 PMID: 25487791
5. Ramirez JA, Anzueto AR (2011) Changing needs of community-acquired pneumonia. J Antimicrob Chemother 66 Suppl 3: iii3-9. doi: 10.1093/jac/dkr094 PMID: 21482567
6. Austrian R, Gold J (1964) Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia. Ann Intern Med 60: 759-776. PMID: 14156606
7. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. (1998) Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. Jama 279: 1452-1457. PMID: 9600479
8. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F (2004) Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164: 502-508. PMID: 15006826
9. Menendez R, Torres A (2007) Treatment failure in community-acquired pneumonia. Chest 132: 1348-1355. PMID: 17934120
10. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. (2000) Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 162: 154-160. PMID: 10903235
11. Aliberti S, Zanaboni AM, Wiemken T, Nahas A, Uppatla S, Morlacchi LC, et al. (2013) Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J 42: 742-749. doi: 10.1183/09031936.00100812 PMID: 23143544
12. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nuesch E, Pletz MW, et al. (2012) Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 39: 611-618. doi: 10.1183/09031936.00098411 PMID: 21965229
13. Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H (2013) Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res 14: 44. doi: 10.1186/1465-9921-14-44 PMID: 23586347
14. Genne D, Sommer R, Kaiser L, Saaidia A, Pasche A, Unger PF, et al. (2006) Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 25: 159-166. PMID: 16528540
15. Blasi F, Ostermann H, Racketa J, Medina J, McBride K, Garau J (2014) Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. Respir Res 15: 6. doi: 10.1186/1465-9921-15-6 PMID: 24450444
16. Aliberti S, Amir A, Peyrani P, Mirsaeidi M, Allen M, Moffett BK, et al. (2008) Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 134: 955-962. doi: 10.1378/chest.08-0334 PMID: 18583514
17. Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, et al. (2014) beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174: 1894-1901. doi: 10.1001/jamainternmed.2014.4887 PMID: 25286173
18. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243-250. PMID: 8995086
19. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377-382. PMID: 12728155
20. Akram AR, Chalmers JD, Taylor JK, Rutherford J, Singanayagam A, Hill AT (2013) An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 19: 1174-1180. doi: 10.1111/1469-0691.12173 PMID: 23438068
21. Menendez R, Torres A, Rodriguez de Castro F, Zalacain R, Aspa J, Martin Villasclaras JJ, et al. (2004) Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 39: 1783-1790. PMID: 15578400
22. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, et al. (2002) Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 162: 1059-1064. PMID: 11996618
23. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, et al. (2012) Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 16: R141. doi: 10.1186/cc11447 PMID: 22839689
24. Hillman K, Chen J, Cretikos M, Bellomo R, Brown D, Doig G, et al. (2005) Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. Lancet 365: 2091-2097. PMID: 15964445
25. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, Flabouris A (2008) Respiratory rate: the neglected vital sign. Med J Aust 188: 657-659. PMID: 18513176
26. Hoogewerf M, Oosterheert JJ, Hak E, Hoepelman IM, Bonten MJ (2006) Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 12: 1097-1104. PMID: 17002609
27. Prina E, Ferrer M, Ranzani OT, Polverino E, Cilloniz C, Moreno E, et al. (2013) Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. Chest 143: 767-775. doi: 10.1378/chest.12-1235 PMID: 23187959
28. Wolach B, Morag H, Drucker M, Sadan N (1990) Thrombocytosis after pneumonia with empyema and other bacterial infections in children. Pediatr Infect Dis J 9: 718-721. PMID: 2235145
29. Dodig S, Raos M, Kovac K, Nogalo B, Benko B, Glojnaric I, et al. (2005) Thrombopoietin and interleukin-6 in children with pneumonia-associated thrombocytosis. Arch Med Res 36: 124-128. PMID: 15847944
30. Mirsaeidi M, Peyrani P, Aliberti S, Filardo G, Bordon J, Blasi F, et al. (2010) Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 137: 416-420. doi: 10.1378/chest.09-0998 PMID: 19837825
31. Semple JW, Italiano JE Jr., Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11: 264-274. doi: 10.1038/nri2956 PMID: 21436837
32. Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S (2014) Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax 69: 609-615. doi: 10.1136/thoraxjnl-2013-203996 PMID: 24743560
33. Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O (2007) Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect 55: 136-140. PMID: 17350105
34. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B (2011) Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 37: 384-392. doi: 10.1183/09031936.00035610 PMID: 20595156
35. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. (2008) Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52: 48-58 e42. doi: 10.1016/j.annemergmed.2008.01.003 PMID: 18342993
36. Menendez R, Martinez R, Reyes S, Mensa J, Polverino E, Filella X, et al. (2009) Stability in community-acquired pneumonia: one step forward with markers? Thorax 64: 987-992. doi: 10.1136/thx.2009.118612 PMID: 19762338
37. Chalmers JD, Singanayagam A, Hill AT (2008) C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 121: 219-225. doi: 10.1016/j.amjmed.2007.10.033 PMID: 18328306